The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Reversal of Type 1 Hepatorenal Syndrome With the Administration of Midodrine and Octreotide
Open accessAbstract
The aim of the study was to verify the effects of the administration of an inhibitor of the release of endogenous vasodilators together with a vasoconstrictor agent in patients with hepatorenal syndrome (HRS). This new medical perspective was compared with a traditional medical approach for HRS, such as the infusion of nonpressor doses of dopamine to produce renal vasodilation. Thirteen patients with type 1 HRS were enrolled in the study. Five of them were treated with the oral administration of midodrine and the parenteral administration of octreotide. In addition, the patients received 50 to 100 mL of 20% human albumin solution daily for 20 days. Midodrine and octreotide were dosed to obtain a stable increase of at least 15 mm Hg of mean arterial pressure. Eight patients were treated with the intravenous administration of nonpressor doses of dopamine (2–4 μg/kg/min) and the same daily amount of albumin. After 20 days of treatment with midodrine and octreotide, an impressive improvement in renal plasma flow (RPF), glomerular filtration rate, and urinary sodium excretion was observed in patients. This was accompanied by a significant reduction in plasma renin activity, plasma vasopressin, and plasma glucagon. No side effects were observed. Three patients were discharged from the hospital. One of them successfully underwent liver transplantation. One of the two remaining patients is still alive after 472 days with a preserved renal function, and the other died from terminal liver failure after 76 days. One of the two patients who were not discharged from the hospital successfully underwent liver transplantation, and the other died from pneumonia after 29 days. Seven out of eight patients who were treated with dopamine experienced a progressive deterioration in renal function and died during the first 12 days. Only one patient recovered renal function and underwent liver transplantation. In conclusion, the long–term administration of midodrine and octreotide seems to be an effective and safe treatment of type 1 HRS in patients with cirrhosis
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis†
Arroyo, V, Ginès, P., Gerbes, A. L., Dudley, F. J., Gentilini, P., Laffi, G., Reynolds, T. B., Ring-Larsen, H., & Schölmerich, J. (1996) · Hepatology · doi:10.1002/hep.510230122 · Cited by 1,703
Schrier, R. W., Arroyo, V., Bernardi, M., Epstein, M., Henriksen, J. H., & Rodés, J. (1988) · Hepatology · doi:10.1002/hep.1840080532 · Cited by 1,623
Lamberts, S. W. J., van der Lely, A.-J., de Herder, W. W., & Hofland, L. J. (1996) · New England Journal of Medicine · doi:10.1056/nejm199601253340408 · Cited by 1,001
Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites
Ginès, A., Escorsell, A., Ginès, P., Saló, J., Jiménez, W., Inglada, L., Navasa, M., Clària, J., Rimola, A., Arroyo, V., et al. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)90031-7 · Cited by 891
Guevara, M., Ginès, P., Fernández‐Esparrach, G., Sort, P., Salmerón, J. M., Jiménez, W., Arroyo, V., & Rodés, J. (1998) · Hepatology · doi:10.1002/hep.510270107 · Cited by 334
Planas, R., Bataller, R., & Rodés, J. (2000) · Current Treatment Options in Gastroenterology · doi:10.1007/s11938-000-0032-9 · Cited by 332
Plasma Endothelin Immunoreactivity in Liver Disease and the Hepatorenal Syndrome
Moore, K., Wendon, J., Frazer, M., Karani, J., Williams, R., & Badr, K. (1992) · New England Journal of Medicine · doi:10.1056/nejm199212173272502 · Cited by 314
[Plasma endothelin immunoreactivity in liver disease and the hepatorenal syndrome].
Møller, S., & Jh, H. (1993) · PubMed · Cited by 295
BOYER, T. D., ZIA, P. K., & Reynolds, T. B. (1979) · PubMed · Cited by 276
Sclerotherapy with or without Octreotide for Acute Variceal Bleeding
Besson, I., Ingrand, P., Person, B., Boutroux, D., Heresbach, D., Bernard, P., Hochain, P., Larricq, J., Gourlaouen, A., Ribard, D., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330904 · Cited by 274
Modulation of the hyperdynamic circulation of cirrhotic rats by nitric oxide inhibition
Pizcueta, P., Piqué, J. M., Fernández, M., Bosch, J., Rodés, J., Whittle, B. J. R., & Moncada, S. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)91451-9 · Cited by 259
Boyer, T. D., Zia, P., & Reynolds, T. B. (1979) · Gastroenterology · doi:10.1016/0016-5085(79)90268-3 · Cited by 252
Role of nitric oxide in the in vitro splanchnic vascular hyporeactivity in ascitic cirrhotic rats
Sieber, C. C., Lopez-Talavera, J. C., & Groszmann, R. J. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)90655-v · Cited by 217
ARROYO, V., PLANAS, R., GAYA, J., DEULOFEU, R., RIMOLA, A., PÉREZ‐AYUSO, O. M., RIVERA, F., & RODES, J. (1983) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1983.tb00100.x · Cited by 214
Sieber, C. C., & Groszmann, R. J. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)91118-n · Cited by 204
McTavish, D., & Goa, K. L. (1989) · Drugs · doi:10.2165/00003495-198938050-00004 · Cited by 159
Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis
Lenz, K., Hörtnagl, H., Druml, W., Reither, H., Schmid, R. W., Schneeweiß, B., Laggner, A. N., Grimm, G., & Gerbes, A. L. (1991) · Gastroenterology · doi:10.1016/0016-5085(91)90734-3 · Cited by 151
Angeli, P., Volpin, R., Piovan, D., Bortoluzzi, A., Craighero, R., Bottaro, S., Finucci, G. F., Casiglia, E., Sticca, A., Toni, R. D., et al. (1998) · Hepatology · doi:10.1002/hep.510280407 · Cited by 136
Self-citationImpaired reactivity of the peripheral vasculature to pressor agents in alcoholic cirrhosis
Ryan, J., Sudhir, K., Jennings, G., Esler, M., & Dudley, F. J. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)90963-d · Cited by 77
Role of nitric oxide and prostacyclin in the control of renal perfusion in experimental cirrhosis
Ros, J., Clària, J., Jiménez, W., Bosch‐Marcé, M., Angeli, P., Arroyo, V., Rivera, F., & Rodés, J. (1995) · Hepatology · doi:10.1002/hep.1840220332 · Cited by 73
Self-citationEffects of a portacaval or peritoneovenous shunt on renin in the hepatorenal syndrome
Schroeder, E. T., Anderson, G. H., & Smulyan, H. (1979) · Kidney International · doi:10.1038/ki.1979.8 · Cited by 69
Moore, K. P. (1997) · Clinical Science · doi:10.1042/cs0920433 · Cited by 61
Effects of somatostatin on renal function in cirrhosis
Ginés, À., Salmerón, J. M., Ginès, P., Jiménez, W., Saló, J., Piera, C., Clària, J., Rivera, F., Arroyo, V., & Rodés, J. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)91446-b · Cited by 51
Midodrine Hydrochloride in Patients on Hemodialysis with Chronic Hypotension
Fang, J., & Huang, C. (1996) · Renal Failure · doi:10.3109/08860229609052795 · Cited by 33
Cited by
Human serum albumin: From bench to bedside
Fanali, G., di Masi, A., Trezza, V., Marino, M., Fasano, M., & Ascenzi, P. (2012) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2011.12.002 · Cited by 1,931
(2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.05.004 · Cited by 1,725
Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis
Salerno, F., Gerbes, A., Ginès, P., Wong, F., & Arroyo, V. (2008) · Postgraduate Medical Journal · doi:10.1136/gut.2006.107789 · Cited by 1,081
Management of adult patients with ascites due to cirrhosis: An update†‡§
Runyon, B. A. (2009) · Hepatology · doi:10.1002/hep.22853 · Cited by 975
Lucey, M. R., Mathurin, P., & Morgan, T. R. (2009) · New England Journal of Medicine · doi:10.1056/nejmra0805786 · Cited by 863
Metadata
- Authors
- Angeli, P., Volpin, R., Gerunda, G., Craighero, R., Roner, P., Merenda, R., Amodio, P., Sticca, A., Caregaro, L., Maffei-Faccioli, A., & Gatta, A.
- Venue
- Hepatology
- Published
- 1999-06
- Volume
- 29
- Issue
- 6
- Pages
- 1690-1697
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2011199481
- Cited by
- 564
- References
- 24
- FWCI
- 11.72
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.